We write about all kinds of cool (and, more importantly, useful) science here at Brainstorm Health Daily. Perhaps none are quite as cool as technologies that can prevent horrible diseases while maximizing user convenience.
And that’s exactly what Merck, the U.S.-based pharma giant, is setting out to do with its experimental HIV treatment combination that could, the company says, be built into a long-lasting implant inserted into patients’ arms.
MK-8591, Merck says, could prove to be longer lasting than existing drugs on the market (this is, notably, missives from the company during a large health care conference focused on AIDS).
As we’ve recently reported, drug makers have begun to shift their HIV/AIDS treatment efforts to focus on easier delivery and usability. ViiV Healthcare, for instance, is developing a monthly HIV shot.
Read on for the day’s news.
Sy Mukherjee, @the_sy_guy, firstname.lastname@example.org
Pinterest wants to help you deal with your stress. Social media is… Stressful. Or at least it can be, according to a slew of studies correlating depression and anxiety with increased social media use. Pinterest, according to MobiHealthNews, wants to do something about that – teaming up with researchers from the Stanford Lab for Mental Health Innovation “to create a new tool aimed at giving users more resources” for answers to questions about stress and serious mental health concerns. (MobiHealthNews)
Senate moves forward on drug pricing proposal. A critical U.S. Senate committee has announced a bipartisan proposal aimed at lowering drug prices. In a statement, the two leading Senators on the committee – Republican Chuck Grassley and Democrat Ron Wyden – said that the “legislation shows that no industry is above accountability.” The main mechanism here would be forcing drug manufacturers to pay rebates to the Medicare insurance program if drug prices are raised beyond a certain amount above inflation. (Reuters)
Japan’s Would-Be Silicon Valley Wants You, by Richard Morgan
The Man Who Wants to See Robots Everywhere, by Adam Lashinsky
What Can We Expect From Boris Johnson? by Phil Boucher
Find past coverage. Sign up for other Fortune newsletters.